135 related articles for article (PubMed ID: 28640529)
1. Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).
Relbo Authen A; Grov I; Karason K; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Dellgren G; Solbu D; Arora S; Andreassen AK; Gullestad L
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640529
[TBL] [Abstract][Full Text] [Related]
2. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
[TBL] [Abstract][Full Text] [Related]
3. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
[TBL] [Abstract][Full Text] [Related]
4. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
[TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
7. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.
Murbraech K; Massey R; Undset LH; Midtvedt K; Holdaas H; Aakhus S
Clin Transplant; 2015 Aug; 29(8):678-84. PubMed ID: 25982053
[TBL] [Abstract][Full Text] [Related]
8. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
Kälble F; Seckinger J; Schaier M; Morath C; Schwenger V; Zeier M; Sommerer C
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28581202
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
10. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
Gullestad L; Eiskjaer H; Gustafsson F; Riise GC; Karason K; Dellgren G; Rådegran G; Hansson L; Gude E; Bjørtuft Ø; Jansson K; Schultz HH; Solbu D; Iversen M
Transpl Int; 2016 Jul; 29(7):819-29. PubMed ID: 27067532
[TBL] [Abstract][Full Text] [Related]
12. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
[TBL] [Abstract][Full Text] [Related]
13. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.
Masetti M; Montalti R; Rompianesi G; Codeluppi M; Gerring R; Romano A; Begliomini B; Di Benedetto F; Gerunda GE
Am J Transplant; 2010 Oct; 10(10):2252-62. PubMed ID: 20486905
[TBL] [Abstract][Full Text] [Related]
14. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
16. Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial.
Andreassen AK; Broch K; Eiskjær H; Karason K; Gude E; Mølbak D; Stueflotten W; Gullestad L;
Transplantation; 2019 Apr; 103(4):781-788. PubMed ID: 30211826
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART.
Potena L; Pellegrini C; Grigioni F; Amarelli C; Livi U; Maccherini M; Masciocco G; Faggian G; Lilla Della Monica P; Gerosa G; Marraudino N; Corda M; Boffini M;
Transplantation; 2018 Mar; 102(3):493-501. PubMed ID: 28930797
[TBL] [Abstract][Full Text] [Related]
19. Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial.
Solberg OG; Stavem K; Ragnarsson A; Ioanes D; Arora S; Endresen K; Benth JŠ; Gullestad L; Gude E; Andreassen AK; Aaberge L
J Heart Lung Transplant; 2016 Aug; 35(8):1010-7. PubMed ID: 27113960
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
Watarai Y; Danguilan R; Casasola C; Chang SS; Ruangkanchanasetr P; Kee T; Wong HS; Kenmochi T; Amante AJ; Shu KH; Ingsathit A; Bernhardt P; Hernandez-Gutierrez MP; Han DJ; Kim MS
Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
